What is the dosage of Adcetris?

Adcetris is available in 1 dosages, including 50 mg Injection

What does Adcetris treat?

Adcetris treats Hodgkin Disease and Immunoblastic Large-Cell Lymphoma

What is Adcetris made of?

Adcetris contains brentuximab vedotin which is a CD30-directed Immunoconjugate

How is Adcetris administered?

Adcetris is administered as a Injectable

What is Adcetris mechanism of action?

Adcetris mechanism of action is CD30-directed Antibody Interactions

Dosage & Administration Drug label Prior authorization Financial assistance

Patient education

Adcetris

(brentuximab vedotin)

brentuximab vedotin 50 MG Injection [Adcetris]

BLACK BOX WARNING

Dosage & administration

* Administer only as an intravenous infusion over 30 minutes .
* The recommended dose as monotherapy is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks .
* The recommended dose in combination with chemotherapy for previously untreated Stage III or IV cHL is 1.2 mg/kg up to a maximum of 120 mg every 2 weeks for a maximum of 12 doses .
* The recommended dose in combination with chemotherapy for previously untreated PTCL is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks for 6 to 8 doses .
* Reduce dose in patients with mild hepatic impairment .

drug label

Adcetris prescribing information

Have more Adcetris questions?

Submit MSL Request

Learn More

Need to report an Adcetris issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Adcetris Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

Coverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Healthcare Provider Request Form

Patient Authorization Form

Healthcare Provider Request Form - Spanish

Patient Authorization Form - Spanish

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Adcetris Financial assistance options

Co-pay savings program

commercial only

Healthcare Provider Request Form

Patient Authorization Form

Healthcare Provider Request Form - Spanish

Patient Authorization Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Healthcare Provider Request Form

Patient Authorization Form

Healthcare Provider Request Form - Spanish

Patient Authorization Form - Spanish

Adcetris Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Adcetris Patient education

Getting started on Adcetris

NOT PROVIDED BY BRANDInstructions For Use - classical Hodgkin Lymphoma (cHL)

NOT PROVIDED BY BRANDInstructions For Use - Peripheral T-cell Lymphoma (PTCL)